Biospect
Advertisement
Bionor Holding AS is a privately held Norwegian biopharmaceutical company dedicated to developing a functional cure for HIV through innovative therapeutic vaccines, specifically Vacc4x and VaccC5. With over USD 100 million invested in research and development, Bionor aims to leverage its immunology expertise to advance its proprietary compounds in the fight against viral diseases.
The company's product pipeline includes three key candidates—Vacc4x, VaccC5, and CRX—which are integral to its Functional HIV Cure strategy. Bionor has successfully completed clinical trials and continues to explore the potential of its vaccine combinations to achieve a breakthrough in HIV treatment.
Generated from the website
Also at this address
You might also like
Partial Data by Infogroup (c) 2025. All rights reserved.
Advertisement